Evolent Health [EVH] vs 10x Genomics [TXG] Detailed Stock Comparison
Evolent Health
NYSE
Loading...
10x Genomics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Evolent Health wins in 13 metrics, 10x Genomics wins in 5 metrics, with 0 ties. Evolent Health appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Evolent Health | 10x Genomics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -10.16 | -8.55 | Evolent Health |
| Price-to-Book Ratio | 1.06 | 2.05 | Evolent Health |
| Debt-to-Equity Ratio | 75.85 | 11.22 | 10x Genomics |
| PEG Ratio | -0.02 | 0.05 | Evolent Health |
| EV/EBITDA | 26.10 | -11.07 | 10x Genomics |
| Profit Margin (TTM) | -5.94% | -13.13% | Evolent Health |
| Operating Margin (TTM) | 0.64% | -2.63% | Evolent Health |
| EBITDA Margin (TTM) | 0.64% | N/A | N/A |
| Return on Equity | -11.04% | -11.30% | Evolent Health |
| Return on Assets (TTM) | -0.21% | -9.45% | Evolent Health |
| Free Cash Flow (TTM) | $-6.13M | $-6.73M | Evolent Health |
| 1-Year Return | -69.51% | -22.26% | 10x Genomics |
| Price-to-Sales Ratio (TTM) | 0.43 | 2.46 | Evolent Health |
| Enterprise Value | $1.89B | $1.23B | Evolent Health |
| EV/Revenue Ratio | 0.86 | 1.90 | Evolent Health |
| Gross Profit Margin (TTM) | 22.59% | 72.34% | 10x Genomics |
| Revenue per Share (TTM) | $19 | $5 | Evolent Health |
| Earnings per Share (Diluted) | $-1.60 | $-0.70 | 10x Genomics |
| Beta (Stock Volatility) | 0.66 | 2.05 | Evolent Health |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Evolent Health vs 10x Genomics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Evolent Health | 0.24% | -5.93% | -14.68% | -29.12% | -12.23% | -28.20% |
| 10x Genomics | -0.86% | 11.46% | -9.26% | 6.04% | 66.75% | -10.92% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Evolent Health | -69.51% | -73.47% | -27.18% | -49.82% | -56.26% | -56.26% |
| 10x Genomics | -22.26% | -50.59% | -92.28% | -75.82% | -75.82% | -75.82% |
News Based Sentiment: Evolent Health vs 10x Genomics
Evolent Health
News based Sentiment: NEGATIVE
October was a significantly negative month for Evolent Health, with a substantial earnings miss, revenue decline, and a sharp drop in share price. While some analysts maintain a positive outlook, the overall narrative points to increased risk and uncertainty for investors, making it a crucial period for the company to demonstrate a turnaround.
10x Genomics
News based Sentiment: MIXED
October brought a strong Q3 earnings beat and positive analyst revisions for 10x Genomics, but these were tempered by a negative full-year EPS forecast and mixed technical indicators. This creates a complex investment picture with both opportunities and risks, making it a significant month for the company.
Performance & Financial Health Analysis: Evolent Health vs 10x Genomics
| Metric | EVH | TXG |
|---|---|---|
| Market Information | ||
| Market Cap | $1.06B | $1.59B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 3,100,400 | 2,746,660 |
| 90 Day Avg. Volume | 3,139,787 | 2,469,420 |
| Last Close | $8.25 | $12.64 |
| 52 Week Range | $7.06 - $27.42 | $6.78 - $20.92 |
| % from 52W High | -69.91% | -39.58% |
| All-Time High | $39.78 (Sep 12, 2022) | $208.99 (Jun 28, 2021) |
| % from All-Time High | -79.26% | -93.95% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.31% | 0.13% |
| Quarterly Earnings Growth | N/A | 0.13% |
| Financial Health | ||
| Profit Margin (TTM) | -0.06% | -0.13% |
| Operating Margin (TTM) | 0.01% | -0.03% |
| Return on Equity (TTM) | -0.11% | -0.11% |
| Debt to Equity (MRQ) | 75.85 | 11.22 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.73 | $6.21 |
| Cash per Share (MRQ) | $1.30 | $3.59 |
| Operating Cash Flow (TTM) | $-33,330,000 | $66.95M |
| Levered Free Cash Flow (TTM) | $-77,390,624 | $58.22M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Evolent Health vs 10x Genomics
| Metric | EVH | TXG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -10.16 | -8.55 |
| Forward P/E | 5.76 | -10.45 |
| PEG Ratio | -0.02 | 0.05 |
| Price to Sales (TTM) | 0.43 | 2.46 |
| Price to Book (MRQ) | 1.06 | 2.05 |
| Market Capitalization | ||
| Market Capitalization | $1.06B | $1.59B |
| Enterprise Value | $1.89B | $1.23B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.86 | 1.90 |
| Enterprise to EBITDA | 26.10 | -11.07 |
| Risk & Other Metrics | ||
| Beta | 0.66 | 2.05 |
| Book Value per Share (MRQ) | $7.73 | $6.21 |
Financial Statements Comparison: Evolent Health vs 10x Genomics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | EVH | TXG |
|---|---|---|
| Revenue/Sales | $483.65M | $154.88M |
| Cost of Goods Sold | $381.18M | $49.44M |
| Gross Profit | $102.47M | $105.45M |
| Research & Development | N/A | $64.25M |
| Operating Income (EBIT) | $4,000 | $-48.53M |
| EBITDA | $25.27M | $-32.89M |
| Pre-Tax Income | $-63.15M | $-33.51M |
| Income Tax | $1.47M | $852,000 |
| Net Income (Profit) | $-64.62M | $-34.36M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | EVH | TXG |
|---|---|---|
| Cash & Equivalents | $246.55M | $377.06M |
| Total Current Assets | $727.93M | $579.73M |
| Total Current Liabilities | $739.10M | $107.90M |
| Long-Term Debt | $663.12M | $70.63M |
| Total Shareholders Equity | $935.52M | $706.90M |
| Retained Earnings | $-845.44M | $-1.50B |
| Property, Plant & Equipment | $5.73M | $55.58M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | EVH | TXG |
|---|---|---|
| Operating Cash Flow | $-23.39M | $35.44M |
| Capital Expenditures | N/A | $-1.89M |
| Free Cash Flow | $-4.03M | $32.46M |
| Debt Repayment | $-62.50M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | EVH | TXG |
|---|---|---|
| Shares Short | 23.10M | 17.35M |
| Short Ratio | 7.22 | 7.58 |
| Short % of Float | 0.20% | 0.22% |
| Average Daily Volume (10 Day) | 3,100,400 | 2,746,660 |
| Average Daily Volume (90 Day) | 3,139,787 | 2,469,420 |
| Shares Outstanding | 115.04M | 122.29M |
| Float Shares | 91.32M | 109.33M |
| % Held by Insiders | 0.02% | 0.02% |
| % Held by Institutions | 1.09% | 1.05% |
Dividend Analysis & Yield Comparison: Evolent Health vs 10x Genomics
| Metric | EVH | TXG |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |